Neumora Therapeutics Overview
Neumora Therapeutics Target Price
Analysts' average 12-month price target for Neumora Therapeutics is $5.
Get informed when a big investor buys or sells
+ FollowShare Price
$0.48
Average Target Price
$5.00
933.5% upside
933.5% upside1 analysts in the last 4 months
High: $5 | Low: $5
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-13 | RBC CapitalBrian Abrahams | $5 | 933.5% upside |  |
| 2026-06-18 | Mizuho Securities | $4 | 726.8% upside | |
| 2026-01-12 | Leerink PartnersMarc Goodman | $8 | 1553.6% upside | |
| 2026-01-05 | Mizuho SecuritiesGraig Suvannavejh | $6 | 1140.2% upside | |
| 2025-12-01 | RBC Capital | $7 | 1346.9% upside | |
| 2025-10-28 | Needham | $8 | 1553.6% upside | |
| 2025-03-07 | Stifel Nicolaus | $2 | 313.4% upside | |
| 2025-01-02 | RBC CapitalBrian Abrahams | $4 | 726.8% upside | |
| 2024-07-22 | NeedhamAmi Fadia | $23 | 4654% upside | |
| 2024-07-08 | Mizuho SecuritiesGraig Suvannavejh | $20 | 4033.9% upside | |
| 2024-06-17 | RBC CapitalBrian Abrahams | $29 | 5894.2% upside | |
| 2024-03-13 | RBC CapitalBrian Abrahams | $31 | 6307.6% upside | |
| 2023-10-10 | Stifel NicolausPaul Matteis | $26 | 5274.1% upside | |
| 2023-10-10 | RBC CapitalBrian Abrahams | $24 | 4860.7% upside | |